SCHEMBL6629147

SCHEMBL6629147

CC(C)(C)OC(=O)N1CC=C(c2ccc(Br)cc2CCl)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK4 Q16654 1/20 0.52
CNR1 P21554 2/20 0.46
HTR6 P50406 1/20 0.46
JAK1 P23458 1/20 0.45
GRM1 Q13255 9/20 0.45
GRM5 P41594 8/20 0.45
SCN9A Q15858 1/20 0.44
NAMPT P43490 1/20 0.44
DGAT2 Q96PD7 1/20 0.44
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GABRA4 P48169 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31223062 0.91 PDK4 (0.53) PDK4CNR1HTR6JAK1GRM1
SCHEMBL6629675 0.90 PDK4 (0.53) PDK4CNR1HTR6JAK1GRM1
SCHEMBL31222963 0.86 PDK4 (0.54) PDK4CNR1HTR6JAK1GRM1
SCHEMBL31443584 0.85 PDK4 (0.56) PDK4CNR1HTR6JAK1GRM1
SCHEMBL31443630 0.84 PDK4 (0.54) PDK4CNR1HTR6JAK1GRM1
SCHEMBL15545634 0.84 PDK4 (0.54) PDK4CNR1HTR6JAK1GRM1
SCHEMBL1199843 0.84 PDK4 (0.54) PDK4CNR1HTR6JAK1GRM1
SCHEMBL30112465 0.84 PDK4 (0.54) PDK4CNR1HTR6JAK1GRM1
SCHEMBL31223106 0.83 PDK4 (0.53) PDK4CNR1HTR6JAK1GRM1
SCHEMBL31192678 0.82 PDK4 (0.55) PDK4CNR1HTR6JAK1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 EP disclosed
US-20030095958-A1 Inhibitors of bace VERTEX PHARMACEUTICALS INCORPORATED 2003-05-22 US disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030095958-A1 Inhibitors of bace BACE2, BACE1, APP PDK4 4236/4885CNR1 4618/4885HTR6 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.